HIGHLIGHTS OF PRESCRIBING INFORMATION ese highlights do not include all the information neede to use RYTELO safely and e RYTELO. RYTELO (imetelstat) for injection, for intravenous use. …

Jun 20, 2024 · Rytelo package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

RYTELO® (imetelstat) is indicated for treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.

Jun 11, 2024 · RYTELO for injection contains imetelstat, an oligonucleotide telomerase inhibitor for intravenous use. Imetelstat sodium is a white to off-white or slightly yellow, amorphous, solid powder.

Rytelo 188 mg powder for concentrate for solution for infusion is a clear, 10 mL Type 1 glass vial with a chlorobutyl rubber stopper and an aluminium flip-off seal with a royal blue plastic cap.

RYTELO (imetelstat) for injection is a sterile, preservative-free, white to off-white or slightly yellow lyophilized powder for intravenous infusion after reconstitution and dilution.

References RYTELO (imetelstat) for intravenous injection [prescribing information online]. Foster City, CA: Geron Corporation. 6/2024. Available at: rytelo_pi.pdf. Accessed 12/9/2024.

Medscape - Myelodysplastic syndrome dosing for Rytelo (imetelstat), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.

Jul 16, 2024 · Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia.

RYTELO prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and RYTELOside effects.